TY - JOUR
T1 - Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens
AU - Ervin, Samantha M.
AU - Li, Hao
AU - Lim, Lauren
AU - Roberts, Lee R.
AU - Liang, Xue
AU - Mani, Sridhar
AU - Redinbo, Matthew R.
N1 - Funding Information:
This work was supported by National Institutes of Health Grants CA098468 and CA207416 (to M. R. R.), the Merck Exploratory Science Center (to M. R. R.), and National Science Foundation Graduate Research Fellowship Program Grant DGS-1650116 (to S. M. E.). This animal study was fully sup-ported by the Department of Defense, United States Army Medical Research and Materiel Command Congressionally Directed Medical Research Pro-grams, 2016 Breast Cancer Research Program Breakthrough Award–Funding Level 1 (CDMRP Log BC161093; GRANT12158914; Award W81XWH-17-1-0023) (Principal Investigator S. M.). Matthew R. Redinbo is a Founder of Sym-berix, Inc., which is developing microbiome-targeted therapeutics. The con-tent is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 Ervin et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
PY - 2019/12/6
Y1 - 2019/12/6
N2 - Gut microbial β-glucuronidase (GUS) enzymes have been suggested to be involved in the estrobolome, the collection of microbial reactions involving estrogens. Furthermore, bacterial GUS enzymes within the gastrointestinal tract have been postulated to be a contributing factor in hormone-driven cancers. However, to date, there has been no experimental evidence to support these hypotheses. Here we provide the first in vitro analysis of the ability of 35 human gut microbial GUS enzymes to reactivate two distinct estrogen glucuronides, estrone-3-glucuronide and estradiol-17-glucuronide, to estrone and estradiol, respectively. We show that certain members within the Loop 1, mini-Loop 1, and FMN-binding classes of gut microbial GUS enzymes can reactivate estrogens from their inactive glucuronides. We provide molecular details of key interactions that facilitate these catalytic processes and present the structures of two novel human gut microbial GUS enzymes related to the estrobolome. Further, we demonstrate that estrogen reactivation by Loop 1 bacterial GUS enzymes can be inhibited both in purified enzymes and in fecal preparations of mixed murine fecal microbiota. Finally, however, despite these in vitro and ex vivo data, we show that a Loop 1 GUS-specific inhibitor is not capable of reducing the development of tumors in the PyMT mouse model of breast cancer. These findings validate that gut microbial GUS enzymes participate in the estrobolome but also suggest that the estrobolome is a multidimensional set of processes on-going within the mammalian gastrointestinal tract that likely involves many enzymes, including several distinct types of GUS proteins.
AB - Gut microbial β-glucuronidase (GUS) enzymes have been suggested to be involved in the estrobolome, the collection of microbial reactions involving estrogens. Furthermore, bacterial GUS enzymes within the gastrointestinal tract have been postulated to be a contributing factor in hormone-driven cancers. However, to date, there has been no experimental evidence to support these hypotheses. Here we provide the first in vitro analysis of the ability of 35 human gut microbial GUS enzymes to reactivate two distinct estrogen glucuronides, estrone-3-glucuronide and estradiol-17-glucuronide, to estrone and estradiol, respectively. We show that certain members within the Loop 1, mini-Loop 1, and FMN-binding classes of gut microbial GUS enzymes can reactivate estrogens from their inactive glucuronides. We provide molecular details of key interactions that facilitate these catalytic processes and present the structures of two novel human gut microbial GUS enzymes related to the estrobolome. Further, we demonstrate that estrogen reactivation by Loop 1 bacterial GUS enzymes can be inhibited both in purified enzymes and in fecal preparations of mixed murine fecal microbiota. Finally, however, despite these in vitro and ex vivo data, we show that a Loop 1 GUS-specific inhibitor is not capable of reducing the development of tumors in the PyMT mouse model of breast cancer. These findings validate that gut microbial GUS enzymes participate in the estrobolome but also suggest that the estrobolome is a multidimensional set of processes on-going within the mammalian gastrointestinal tract that likely involves many enzymes, including several distinct types of GUS proteins.
UR - http://www.scopus.com/inward/record.url?scp=85076197202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076197202&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA119.010950
DO - 10.1074/jbc.RA119.010950
M3 - Article
C2 - 31636122
AN - SCOPUS:85076197202
SN - 0021-9258
VL - 294
SP - 18586
EP - 18599
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 49
ER -